UK Markets close in 8 hrs 17 mins

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8500+0.2300 (+8.78%)
At close: 04:00PM EDT

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904
https://www.aldeyra.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees12

Key executives

NameTitlePayExercisedYear born
Dr. Todd C. Brady M.D., Ph.D.CEO, Pres & Director859.4kN/A1972
Mr. Joshua Reed M.B.A.Chief Financial Officer616.4kN/A1973
Dr. Stephen G. Machatha Ph.D.Chief Devel. Officer478.4kN/A1977
Mr. Kelly MizerVP of Commercial Strategy & OperationsN/AN/AN/A
Mr. Bruce Greenberg CPA, M.B.A.VP & ControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Corporate governance

Aldeyra Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.